ReviewEuropean radiology2020
Imaging of sarcopenia: old evidence and new insights.
Review in European radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 233 papers, 13 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
233 citing papers in PubMed, 13 syntheses or guidelines pooled it, 375 citations in OpenAlex.
- Clinical characteristics and mortality risk of sarcopenia in interstitial lung disease: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Sarcopenia defined by serum creatinine and cystatin C predicts poor survival outcomes in patients with cancers.BMC geriatrics · 2025Pooled it
- The impact of sarcopenia on sarcoma patients: a systematic review and meta-analysis.La Radiologia medica · 2025Pooled it
- Muscle elasticity variations in assessing age-related changes in adults - A systematic review.Geriatrics & gerontology international · 2025Pooled it
- Low lean mass and all-cause mortality risk in the middle-aged and older population: a dose-response meta-analysis of prospective cohort studies.Frontiers in medicine · 2025Pooled it
- Non invasive techniques for direct muscle quality assessment after exercise intervention in older adults: a systematic review.BMC geriatrics · 2024Pooled it
- Start with muscle mass or muscle strength in diagnosis and management of sarcopenia? A systematic review of guidance documents.Asia Pacific journal of clinical nutrition · 2024Pooled it
- Myosteatosis and the clinical outcomes of patients with liver cirrhosis: A meta-analysis.PloS one · 2024Pooled it
- Computed Tomography-Defined Fat Composition as a Prognostic Marker in Gastric Adenocarcinoma: A Systematic Review and Meta-Analysis.Digestive diseases (Basel, Switzerland) · 2023Pooled it
- Prevalence and mortality risk of low skeletal muscle mass in critically ill patients: an updated systematic review and meta-analysis.Frontiers in nutrition · 2023Pooled it
- Low Skeletal Muscle Mass Predicts Relevant Outcomes in Palliative Urological Oncology: A Systematic Review and Meta-Analysis.Urologia internationalis · 2023Pooled it
- Evaluation of Appendicular Muscle Mass in Sarcopenia in Older Adults Using Ultrasonography: A Systematic Review and Meta-Analysis.Gerontology · 2022Pooled it
- The magnitude and progress of lean body mass, fat-free mass, and skeletal muscle mass loss following bariatric surgery: A systematic review and meta-analysis.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2022Pooled it
- A nomogram based on psoas muscle index predicting long-term cirrhosis incidence in non-cirrhotic patients with HBV-related acute‑on‑chronic liver failure.Scientific reports · 2023Trial
- Association between reduced cervical extensor muscle mass and postoperative outcomes after single-door laminoplasty in elderly patients with cervical spondylotic myelopathy: a retrospective study.Annals of medicine · 2026Article
- Strengthening muscle for healthy ageing: innovative treatments for sarcopenia.Nature reviews. Drug discovery · 2026Review
- Clinical impact of CT-defined sarcopenia on long-term oncological outcomes in gastric cancer: validation of muscle mass cut-offs established according to EWGSOP recommendations.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Article
- Association between low skeletal muscle mass assessed by deep learning-based CT and MASLD: a prospective cohort study.Diabetology & metabolic syndrome · 2026Article
- Reference values and cut-points for trunk myopenia and myosteatosis in Chinese adults: a secondary analysis of the China Action on Spine and Hip study.Quantitative imaging in medicine and surgery · 2026Article
- Interplay between sarcopenia and type 2 diabetes: mechanisms, implications, and therapeutic prospects.Nutrition & diabetes · 2026Review
173 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To date, sarcopenia is considered a patient-specific imaging biomarker able to predict clinical outcomes. Several imaging modalities, including dual-energy X-ray absorptiometry (DXA), computed tomography (CT), magnetic resonance (MR), and ultrasound (US), can be used to assess muscle mass and quality and to achieve the diagnosis of sarcopenia. With different extent, all these modalities can provide quantitative data, being thus reproducible and comparable over time. DXA is the one most commonly used in clinical practice, with the advantages of being accurate and widely available, and also being the only radiological tool with accepted cutoff values to diagnose sarcopenia. CT and MR are considered the reference standards, allowing the evaluation of muscle quality and fatty infiltration, but their application is so far mostly limited to research. US has been always regarded as a minor tool in sarcopenia and has never gained enough space. To date, CT is probably the easiest and most promising modality, although limited by the long time needed for muscle segmentation. Also, the absence of validated thresholds for CT measurements of myosteatosis requires that future studies should focus on this point. Radiologists have the great potential of becoming pivotal in the context of sarcopenia. We highly master imaging modalities and know perfectly how to apply them to different organs and clinical scenarios. Similarly, radiologists should master the culture of sarcopenia, and its clinical aspects and relevant implications for patient care. The medical and scientific radiological community should promote specific educational course to spread awareness among professionals. KEY POINTS: • DXA is an accurate, reproducible, and widely available imaging modality to evaluate body composition, being the most commonly used radiological tool to diagnose sarcopenia in clinical practice • CT and MR are the gold standard imaging modalities to assess muscle mass and quality, but no clear cutoff values have been reported to identify sarcopenia, limiting the application of these modalities to research purposes • US has shown to be accurate in the evaluation of muscle trophism, especially in the thigh, but its current application in sarcopenia is limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.